Bank OZK Raises Quarterly Dividend to 46 Cents Per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy GHRS?
Source: Benzinga
- Dividend Increase: Bank OZK raised its quarterly dividend from 45 cents to 46 cents per share, indicating sustained profitability and likely attracting more investor interest while enhancing shareholder returns.
- Stock Price Reaction: Following the announcement, Bank OZK's shares rose 0.1% to $47.10 in after-hours trading, reflecting a positive market response to its dividend policy, which may bolster investor confidence.
- Executive Departure: Photronics, Inc. disclosed that Chief Technology Officer Dr. Christopher Progler will step down, resulting in a 1.5% increase in the company's stock price to $33.90 in after-hours trading, suggesting a favorable market reaction to the leadership change.
- FDA Update Anticipation: GH Research PLC announced it will provide an update on its FDA IND status and Phase 3 program for GH001, leading to a 22.4% surge in its stock price to $16.20 in after-hours trading, indicating strong market anticipation for its drug development progress.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GHRS
Wall Street analysts forecast GHRS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.340
Low
19.00
Averages
28.60
High
35.00
Current: 18.340
Low
19.00
Averages
28.60
High
35.00
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
Trump Signs Executive Order on Psychedelics, Boosting Compass Pathways Stock
- Stock Surge: Compass Pathways' stock surged significantly after President Trump signed an executive order related to psychedelic drugs, reflecting market optimism regarding the company's future, particularly in mental health applications.
- Policy Impact: The executive order may create a more favorable regulatory environment for the research and development of psychedelics, potentially accelerating Compass Pathways' innovation in new therapies and enhancing its competitive position.
- Investor Confidence: Increased attention on psychedelics has drawn more investors to the sector, benefiting Compass Pathways as it is expected to attract more capital to support its R&D projects.
- Industry Outlook: As the therapeutic potential of psychedelics for mental health issues gains recognition, Compass Pathways is poised to lead in this emerging market, driving long-term growth for the company.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Trump Administration to Examine Ibogaine Research for PTSD Funding
- Government Focus on Ibogaine: The Trump administration plans to closely examine ibogaine's safety and effectiveness, maintaining its Schedule I classification, which indicates a cautious approach to its potential medical applications.
- Research Funding Opening: President Trump is expected to sign an executive order aimed at unlocking federal funding for research into ibogaine's effectiveness for PTSD and traumatic brain injuries, particularly among veterans, signaling a significant policy shift.
- Stock Price Surge: Following the news, shares of Psyence Biomedical (PBM) surged over 141% on Thursday, potentially marking its best trading session, reflecting strong market confidence in the company's natural-derived therapies.
- Market Sentiment Extremely Bullish: On Stocktwits, retail sentiment around PBM stock remained in the 'extremely bullish' territory with message volume spiking, despite the stock having fallen approximately 95% over the past year.
See More
GH001 Shows Promising Results in Treatment-Resistant Depression Study
- Clinical Trial Results Published: GH Research PLC has published the Phase 2b trial results of GH001 in JAMA Psychiatry, demonstrating significant efficacy in treatment-resistant depression (TRD) patients, achieving the primary endpoint with a MADRS reduction of 15.5 points from baseline (P<0.0001), indicating GH001's potential to transform current treatment paradigms.
- Efficacy Independence Analysis: A forthcoming article in Psychopharmacology Bulletin highlights that GH001's efficacy is independent of prior antidepressant treatment failures, with Day 8 remission rates ranging from 53.9% to 63.6% among patients with 2 to 5 prior failures, showcasing GH001's unique advantage.
- Long-Term Remission Rate Improvement: At the end of the trial, 6-month remission rates reached 61.5% to 85.7% in the same patient groups, contrasting sharply with the declining remission rates observed in the STAR*D trial with successive treatment failures, suggesting GH001 may offer new hope for patients with extensive treatment histories.
- Advancement of Global Trial Plans: CEO Velichka Valcheva stated that the publication in JAMA Psychiatry provides independent peer-reviewed validation of GH001's Phase 2b findings, supporting the company's efforts to advance GH001 into global pivotal trials, signaling future strategic positioning in the depression treatment landscape.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
Trump Signs Executive Order on Psychedelics, Boosting Compass Pathways Stock
- Stock Surge: Compass Pathways' stock surged significantly after President Trump signed an executive order related to psychedelic drugs, reflecting market optimism regarding the company's future, particularly in mental health applications.
- Policy Impact: The executive order may create a more favorable regulatory environment for the research and development of psychedelics, potentially accelerating Compass Pathways' innovation in new therapies and enhancing its competitive position.
- Investor Confidence: Increased attention on psychedelics has drawn more investors to the sector, benefiting Compass Pathways as it is expected to attract more capital to support its R&D projects.
- Industry Outlook: As the therapeutic potential of psychedelics for mental health issues gains recognition, Compass Pathways is poised to lead in this emerging market, driving long-term growth for the company.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Trump Administration to Examine Ibogaine Research for PTSD Funding
- Government Focus on Ibogaine: The Trump administration plans to closely examine ibogaine's safety and effectiveness, maintaining its Schedule I classification, which indicates a cautious approach to its potential medical applications.
- Research Funding Opening: President Trump is expected to sign an executive order aimed at unlocking federal funding for research into ibogaine's effectiveness for PTSD and traumatic brain injuries, particularly among veterans, signaling a significant policy shift.
- Stock Price Surge: Following the news, shares of Psyence Biomedical (PBM) surged over 141% on Thursday, potentially marking its best trading session, reflecting strong market confidence in the company's natural-derived therapies.
- Market Sentiment Extremely Bullish: On Stocktwits, retail sentiment around PBM stock remained in the 'extremely bullish' territory with message volume spiking, despite the stock having fallen approximately 95% over the past year.
See More
GH001 Shows Promising Results in Treatment-Resistant Depression Study
- Clinical Trial Results Published: GH Research PLC has published the Phase 2b trial results of GH001 in JAMA Psychiatry, demonstrating significant efficacy in treatment-resistant depression (TRD) patients, achieving the primary endpoint with a MADRS reduction of 15.5 points from baseline (P<0.0001), indicating GH001's potential to transform current treatment paradigms.
- Efficacy Independence Analysis: A forthcoming article in Psychopharmacology Bulletin highlights that GH001's efficacy is independent of prior antidepressant treatment failures, with Day 8 remission rates ranging from 53.9% to 63.6% among patients with 2 to 5 prior failures, showcasing GH001's unique advantage.
- Long-Term Remission Rate Improvement: At the end of the trial, 6-month remission rates reached 61.5% to 85.7% in the same patient groups, contrasting sharply with the declining remission rates observed in the STAR*D trial with successive treatment failures, suggesting GH001 may offer new hope for patients with extensive treatment histories.
- Advancement of Global Trial Plans: CEO Velichka Valcheva stated that the publication in JAMA Psychiatry provides independent peer-reviewed validation of GH001's Phase 2b findings, supporting the company's efforts to advance GH001 into global pivotal trials, signaling future strategic positioning in the depression treatment landscape.
See More
